Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients (Q44270021)

1 December 2017

Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients (English)

1 reference

1 December 2017

0 references

0 references

0 references

Meena Arvindakshan

1

1 reference

1 December 2017

Sandhya Sitasawad

2

1 reference

1 December 2017

Vijay Debsikdar

3

1 reference

1 December 2017

Madhav Ghate

4

1 reference

1 December 2017

Denise Evans

5

1 reference

1 December 2017

David F Horrobin

6

1 reference

1 December 2017

Crispin Bennett

7

1 reference

1 December 2017

Prabhakar K Ranjekar

8

1 reference

1 December 2017

Sahebarao P Mahadik

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

1 December 2017

Biological Psychiatry

1 reference

1 December 2017

53

1 reference

1 December 2017

1

1 reference

1 December 2017

56-64

1 reference

Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Advancing a neurodevelopmental origin for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Deficit and nondeficit forms of schizophrenia: the concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Schizophrenia as a membrane lipid disorder which is expressed throughout the body

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

The membrane hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Fatty acid levels in the brains of schizophrenics and normal controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

No differences in phospholipase-A2 activity between acute psychiatric patients and controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

The positive and negative syndrome scale (PANSS) for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Erythrocyte membrane phospholipids in psychotic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Radiation Effects on Membranes: I. Vitamin E Deficiency and Lipid Peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

The effect of ischemia and recirculation, hypoxia and recovery on anti-oxidant factors and beta-adrenoceptor density. Is the damage in the erythrocytes a reflection of brain damage caused by complete cerebral ischemia and by hypoxia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Free radical pathology and antioxidant defense in schizophrenia: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Elevated plasma lipid peroxides at the onset of nonaffective psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Fatty acids in plasma and red cell membranes in normal humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Free radical pathology in schizophrenia: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Omega-3 fatty acids in health and disease and in growth and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Dyskinesias and their treatment with essential fatty acids: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Do essential fatty acids play a role in brain and behavioral development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Implications of normal brain development for the pathogenesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Rationale for the study of early intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

Increased turnover of platelet phosphatidylinositol in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901443-9

10.1016/S0006-3223(02)01443-9

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference